BEYOND AIR INC. - COM

Beyond Air® To Participate in the 35th Annual Piper Sandler Healthcare Conference

15 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Financial Results for Second Quarter of Fiscal Year 2024

13 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Presents Positive First-in-Human Clinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

03 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast

19 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® To Participate in the Truist Securities BioPharma Symposium

17 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Publishes Pre-Clinical Data in Cells Demonstrating that the Combination of Ultra-High Concentration Nitric Oxide (UNO) and Anti-mPD-1 Therapy Improves Tumor Regression Rates and Survival in Mice

17 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) in Combination with Checkpoint Inhibitor Therapy During the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

16 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

Beyond Air® Receives Innovative Technology Contract from Vizient for LungFit®PH

16 Oct 2023 06:00:00 By Nasdaq GlobeNewswire

Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 Oct 2023 06:30:00 By Nasdaq GlobeNewswire

Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference

02 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting

27 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder

18 Sep 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® To Participate in the 2023 Cantor Global Healthcare Conference

06 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024

10 Aug 2023 15:05:01 By Nasdaq GlobeNewswire

Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)

07 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® To Participate in BTIG’s 2023 Virtual Biotechnology Conference

01 Aug 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023

22 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Secures up to $40 Million Debt Financing

15 Jun 2023 15:10:00 By Nasdaq GlobeNewswire

Beyond Air® Licenses Commercial Rights to Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors for the Treatment of Autism Spectrum Disorder from Hebrew University of Jerusalem

15 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast

16 May 2023 15:05:00 By Nasdaq GlobeNewswire